NATH BIOGENES (INDIA)
|
|
BOM : 537291     NSE : NATHBIOGEN     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Good [Stock is Cheap] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Mild Upward Pledged Shares : None or < 25% |
Nov 29,2024 |
Price(EOD): ₹ 191.70
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Agriculture |
MCap: ₹ 364.23 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
NATH BIOGENES (INDIA) | 6.4% | 3.6% | -8% |
BOMBAY BURMAH TRADING CORPORATION | -4.7% | -12.5% | 72.5% |
KAVERI SEED COMPANY | 3.3% | 2.6% | 45.7% |
VENKYS (INDIA) | 3% | 2.3% | -12% |
BOMBAY SUPER HYBRID SEEDS | 21.9% | 6.8% | -35% |
TIERRA AGROTECH | -1.4% | 3.3% | -36% |
INDO US BIOTECH | -0.1% | 5.6% | 9.1% |
MANGALAM SEEDS | 1.8% | -9.1% | -14.2% |
SHREE OSWAL SEEDS AND CHEMICALS | 8% | -6% | -59.5% |
FUNDAMENTAL ANALYSIS OF NATH BIOGENES (INDIA)
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF NATH BIOGENES (INDIA)
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
9.12
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 39.96 Cr
[Latest Qtr - Sep2024 - Consolidated Results ] 0.6
P/B Calculated based on Book Value of Rs 609.92 Cr
[Latest Year - Mar2024 - Consolidated Results ] 1.04
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 350.84 Cr
[Latest Qtr - Sep2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
-100% -36% -29% |
SHARE PRICE MOMENTUM OF NATH BIOGENES (INDIA)
NATH BIOGENES (INDIA) vs SENSEX
DEBT OF NATH BIOGENES (INDIA)
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.18 0.18 0.17 0.18 |
0.18 0.18 0.17 0.18 |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF NATH BIOGENES (INDIA)
Pledged Promoter Shares |
16.38 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF NATH BIOGENES (INDIA)
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-86.8% -86.83% -96.77% -96.66% |
42.65% -3.37% -41.2% -25.78% |
QtrlyTrend |
-6 | |
Latest Qtr: Sep2024 | ||
Quarterly Result Analysis → |
NATH BIOGENES (INDIA) related INDICES
You may also like the below Video Courses
FAQ about NATH BIOGENES (INDIA)
Is NATH BIOGENES (INDIA) good for long term investment?
As on Nov 29,2024, the Fundamentals of NATH BIOGENES (INDIA) look Strong and hence it may be good for long term investment! See Financial Performance of NATH BIOGENES (INDIA) . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is NATH BIOGENES (INDIA) UnderValued or OverValued?
As on Nov 29,2024, NATH BIOGENES (INDIA) is Under Valued based on the estimates of intrinsic value and hence may be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of NATH BIOGENES (INDIA) ?
As on Nov 29,2024, the Intrinsic Value of NATH BIOGENES (INDIA) is Rs. 297.31 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 12,950,684.21
Fair Value [Median EV / Sales Model] : Rs. 297.31
Fair Value [Median Price / Sales Model] : Rs. 268.30
Estimated Median Fair Value of NATH BIOGENES (INDIA) : Rs. 297.31
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.